Needham analyst Kyle Peterson maintains Cardlytics (NASDAQ:CDLX) with a Buy and lowers the price target from $14 to $8.
Needham Maintains Buy on Cardlytics, Lowers Price Target to $8
Needham analyst Kyle Peterson maintains Cardlytics (NASDAQ:CDLX) with a Buy and lowers the price target from $14 to $8.
Related Posts
Aileron Therapeutics Announces Acquisition Of Lung Therapeutics; Financing Proceeds Of ~$18M From A Private Placement Anticipated To Fund Completion Of The Ongoing Phase 1b Clinical Study Of LTI-03 In IPF And For General Corporate Purposes
Acquisition includes multiple clinical stage, orphan pulmonary disease candidates, including LTI-03, a Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis (IPF)Financing
Auburn National Bancorporation, Inc. Announces Leadership Succession Plan; Bob Dumas To Retire On December 31, 2022 As President And CEO; David Hedges To Be Named President And CEO; James Walker To Be Named SVP and CFO Effective January 1, 2023
Bob Dumas to Remain Chairman and a Director, but Retire on December 31, 2022 as President and CEO
David Hedges, EVP and CFO to be named President and CEO effective January 1, 2023
James Walker, SVP and CAO to be named
What 4 Analyst Ratings Have To Say About Aspen Technology
Over the past 3 months, 4 analysts have published their opinion on Aspen Technology (NASDAQ:AZPN) stock. These analysts…